| Title |
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
|
|---|---|
| Published in |
Journal of Hematology & Oncology, November 2013
|
| DOI | 10.1186/1756-8722-6-88 |
| Pubmed ID | |
| Authors |
Akintunde Akinleye, Parthu Avvaru, Muhammad Furqan, Yongping Song, Delong Liu |
| Abstract |
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that regulate diverse cellular processes including proliferation, adhesion, survival, and motility. Dysregulated PI3K pathway signaling occurs in one-third of human tumors. Aberrantly activated PI3K signaling also confers sensitivity and resistance to conventional therapies. PI3K has been recognized as an attractive molecular target for novel anti-cancer molecules. In the last few years, several classes of potent and selective small molecule PI3K inhibitors have been developed, and at least fifteen compounds have progressed into clinical trials as new anticancer drugs. Among these, idelalisib has advanced to phase III trials in patients with advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma. In this review, we summarized the major molecules of PI3K signaling pathway, and discussed the preclinical models and clinical trials of potent small-molecule PI3K inhibitors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 205 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| India | 1 | <1% |
| United Kingdom | 1 | <1% |
| Belgium | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 200 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 34 | 17% |
| Researcher | 29 | 14% |
| Student > Bachelor | 27 | 13% |
| Student > Master | 24 | 12% |
| Other | 14 | 7% |
| Other | 35 | 17% |
| Unknown | 42 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 25% |
| Agricultural and Biological Sciences | 30 | 15% |
| Biochemistry, Genetics and Molecular Biology | 29 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 8% |
| Chemistry | 15 | 7% |
| Other | 20 | 10% |
| Unknown | 43 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2022.
All research outputs
#2,437,376
of 23,283,373 outputs
Outputs from Journal of Hematology & Oncology
#178
of 1,209 outputs
Outputs of similar age
#28,763
of 304,578 outputs
Outputs of similar age from Journal of Hematology & Oncology
#1
of 13 outputs
Altmetric has tracked 23,283,373 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,209 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 304,578 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.